- Home
- SPFI vs BBNX Comparison
SPFI vs BBNX Comparison
Compare SPFI & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | BBNX |
|---|---|---|
| Founded | 1941 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.4M | 613.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | SPFI | BBNX |
|---|---|---|
| Price | $41.58 | $13.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $42.25 | $26.73 |
| AVG Volume (30 Days) | 56.1K | ★ 1.2M |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.65 | $35.03 |
| Revenue Next Year | $9.40 | $33.24 |
| P/E Ratio | $16.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.01 | $8.89 |
| 52 Week High | $44.00 | $32.71 |
Technical Indicators
Market Signals| Indicator | SPFI | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 34.38 |
| Support Level | $41.33 | $12.48 |
| Resistance Level | $41.91 | $15.64 |
| Average True Range (ATR) | 1.12 | 1.17 |
| MACD | -0.18 | 0.47 |
| Stochastic Oscillator | 9.36 | 58.10 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.